SELLAS Life Sciences has transformed its shareholder base and strengthened its balance sheet, doubling institutional ownership to 36.34% and securing about $138.3 million in cash. This financial and structural improvement comes as the company approaches the critical REGAL trial readout, a key binary event that will significantly impact its future. Passive and index funds now dominate ownership, reducing volatility, while short interest has declined. The company maintains its Greater China license, providing additional strategic value post-readout.
The NEOS S&P 500 High Income ETF (SPYI) is rated a buy due to its attractive 12% distribution yield combined with broad S&P 500 exposure. It uses an actively managed options overlay on the S&P 500 to generate additional returns without significantly ...
The August 2026 Top 25 High-Growth Dividend Stocks list highlights quality companies trading below their intrinsic value, offering an average starting dividend yield of 1.28% and a five-year dividend growth rate of 17.19%. The list is estimated to de...
Meta's stock is currently trading at a forward price-to-earnings (P/E) ratio of 17, which is lower than its average over the past five years. This suggests that the stock might be undervalued and could represent a buying opportunity for investors. Me...
Dynex Capital has expanded its portfolio to $27.6 billion in Q2 2026, up 11% from the previous quarter and significantly from $8.6 billion two years ago. The company has moved from tactical asset rotation to using interest-rate swaps, aligning its pe...
Rosen Law Firm has filed a class action lawsuit on behalf of investors who bought Wise Group plc securities between May 11 and July 23, 2026. The lawsuit alleges that Wise Group made false or misleading statements about its regulatory risks, particul...
